ClinicalTrials.gg
CompletedNCT02195518Updated Nov 4, 2019Results posted

Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study

A Phase 4 interventional study of Tenofovir disoproxil fumarate in Hepatitis B, Chronic, sponsored by GlaxoSmithKline. Completed at 12 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-04.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
213
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
12th of 50
213 · median 117
Started
2015
with 6 others
Phase 4
22 of 50
none open now
Registered
32nd of 50
by date
Lead sponsor
7 of 50
GlaxoSmithKline

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 12th largest by enrollment, is one of 7 that started in 2015, is one of 22 in phase 4, and was the 32nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

This is a phase IV, single-arm, open-label, multi-centre study to assess the efficacy of TDF in Chronic hepatitis B (CHB) subjects following failure of multiple Nucleos(t)ide analogues (NAs). The study will enrol 200 CHB subjects following failure of multiple NAs. Subjects will be assessed for eligibility at a screening visit, with eligible subjects returning for a baseline assessment after approximately 4 weeks (Screening phase). In the treatment phase all enrolled subjects will receive open label TDF at a dose of 300 milligrams (mg) orally once daily. All the eligible study subjects will undergo safety and efficacy assessments every 12 weeks for a total of 14 visits. Tenofovir disoproxil fumarate, the oral pro-drug of tenofovir (TFV), is a nucleotide analogue that inhibits viral polymerases by direct binding and after incorporation into deoxyribonucleic acid (DNA), by termination of the DNA) chain. TDF is a highly potent treatment in treatment-naïve and lamivudine (LAM) resistant CHB patients. The purpose of our study is to evaluate the efficacy of TDF treatment in Chinese CHB patients following failure of multiple NAs. In addition, the study will also explore the relationship of baseline factors and early HBV DNA suppression to long-term virological response. The efficacy of TDF in multi-drug resistant patients will be analysed separately. The data generated by this study could then be used to optimize the clinical application of TDF and provide new evidence for management of the HBV infections following failure of multiple NAs. The result of this study will help Chinese physicians better manage the CHB patients following failure of multiple NAs.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

Keywords

  • Chronic Hepatitis B
  • Tenofovir disoproxil fumarate
  • Failure of multiple NAs treatment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18-65years (inclusive). Male or female; a female is eligible to enter and participate in this study if she is of: Non- (i.e., physiologically incapable of becoming pregnant, including any female who is ); or,
  • Child-bearing potential, has a negative serum pregnancy test at baseline, and agrees to one of the following methods for avoidance of pregnancy during the period of the study and until 30 days after last dose of study medication: Oral , either combined or progestogen alone, Injectable progestogen, Implants of levonorgestrel, Oestrogenic vaginal ring, Percutaneous contraceptive patches., Intrauterine device (IUD) or intrauterine system (IUS) showing that the expected failure rate is less than 1% per year as stated in the IUD or IUS product label, Has a male partner who is sterilised, Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film /cream/suppository).
  • The ability to understand and sign a written prior to any study-related procedure and comply with the requirements of the study.
  • Positive for more than 6 months, and anti-HBs negative.
  • Serum HBV DNA level >=200 IU/mL at study screening (Use central lab results).
  • Experienced multiple NAs treatment failure which is defined as HBV DNA greater than 200 IU/mL after at least two NAs treatment (at least 6 months continuous treatment for each NA(s), total duration is no less than 12 months). In addition, subjects judged by the treating physician to have adhered to previous NA therapy.
  • Agreement not to participate in any other trials or to undertake other HBV systemic antiviral or interferon (IFN) regimens during participation in this study.

Exclusion criteria

Exclusion Criteria:

  • Hepatocellular carcinoma as evidenced by one of the following: Suspicious foci on ultrasound or radiological examination, Normal ultrasound but a history of rising serum alpha-fetoprotein and serum alpha-fetoprotein >20 nanogram (ng) per mL at screening.
  • Clinical signs of decompensated liver disease at baseline. These may include but are not limited to:Total serum >1.5 x (ULN), >1.3, Serum albumin \<32grams per Liter (g/L), History of clinical hepatic decompensation (e.g., ascites, variceal bleeding, or encephalopathy).
  • less than 70 milliliter per minutes (mL/min).
  • >10 times ULN at screening or history of acute exacerbation leading to transient decompensation.
  • \<8 grams per deciliter (g/dL), \<1.0 x 10\^9 per Liter, \<75 x 10\^9 per Liter.
  • Documented co-infection with hepatitis A (HAV), (HCV), hepatitis delta virus (HDV), hepatitis E virus (HEV) or (HIV). For HCV co-infection, subjects who are anti-HCV positive and in whom HCV RNA is undetectable are considered to be not eligible for enrolment.
  • Evidence of active liver disease due to hepatitis (antinuclear antibody titre >1:160)
  • Any serious or active medical or psychiatric illnesses other than which, in the opinion of the Investigator, would interfere with subject treatment, assessment or compliance with the protocol. This would include any uncontrolled renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, pathological fractures or cancer.
  • Active alcohol or drug abuse or history of alcohol or drug abuse considered by the Investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.
  • A female who is breastfeeding or plan to breast.
  • Use of therapy, immunomodulatory therapy [including Pegylated interferon (PEG-IFN) and short-acting interferon or thymosin alpha], systemic cytotoxic agents within the previous 6 months prior to screening.
  • Planned for liver transplantation or previous liver transplantation.
  • Receipt of TDF within 6 months prior to screening.
  • Therapy with nephrotoxic drugs (e.g., aminoglycosides, amphotercin B, vancomycin, cidofovir, foscarnet, cis-platinum, pentamidine etc.) or competitors of renal excretion (e.g., probenecid) within 2 months prior to study screening or the expectation that subject will receive any of these during the course of the study.
  • History of to nucleoside and/or nucleotide analogues and/or any component of study medication.
  • Inability to comply with study requirements as determined by the study Investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    Tenofovir Disoproxil Fumarate

    All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.

    Drug: Tenofovir disoproxil fumarate

Interventions

  • Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144

    HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Week 144. A 95 percent confidence interval (CI) was constructed by normal approximation and continuity correction method. Percentage of participants with serum HBV DNA \<20 IU/mL at Week 144 have been presented. The Modified Intent-to-treat (mITT) Population was defined as all recruited participants who received at least one dose of study medication.

    Time frame: At Week 144

Secondary outcomes

  1. Percentage of Participants With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48 and 96

    HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Weeks 48 and 96. Virological response was assessed by proportion of participants with serum serum HBV \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96. Percentage of participants with serum HBV DNA \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96 have been presented.

    Time frame: At Weeks 48 and 96

  2. Percentage of Participants in the Subgroup With Confirmed Multi-drug Resistance Mutations at Baseline With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48, 96 and 144

    Serum samples were collected and analyzed for HBV DNA levels at indicated time points. Resistance surveillance of the HBV polymerase gene were performed by direct sequencing for all participants at Baseline. Day 0 was considered as Baseline. Percentage of participants in the subgroup with confirmed multi-drug resistance mutations at Baseline with serum HBV DNA \<20 IU/mL and serum HBV DNA \<69 IU/mL at Weeks 48, 96 and 144 have been presented.

    Time frame: At Weeks 48, 96, and 144

  3. Change From Baseline in Logarithm to the Base 10 (Log 10) Reduction in Serum HBV DNA at Week 48, 96 and 144

    Log10 reduction in serum HBV DNA was analyzed by patterns of mutation. The patterns of mutation were summarized by 2 categories. Category 1 included wild-type, LAM-R (Lamivudine-resistant), ADV-R (Adefovir-resistant) and ETV-R (Entecavir-resistant). Category 2 included Wild type, ADV-R single mutation, ADV-R double mutation and other mutation. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks 48,96, and 144

  4. Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion or Hepatitis B s Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 48, 96, and 144

    Serological response was assessed at Weeks 48, 96 and 144 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss, HBeAg Seroconversion, HBsAg Loss and HBsAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.

    Time frame: At Weeks 48, 96 and 144

  5. Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 48, 96, and 144

    Serological response was assessed at Weeks 48, 96 and 144 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.

    Time frame: At Weeks 48,96, and 144

  6. Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, and 144 in Participants Who Had Abnormal ALT at Baseline

    Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization was defined as measurement less than or equal to the upper limit of the normal range. Normal range for ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, and 144 in Participants who had abnormal ALT at Baseline (Day 0) have been presented.

    Time frame: At Weeks 48, 96, and 144

  7. Percentage of Participants Who Experienced Viral Breakthrough up to Week 144

    Viral breakthrough was defined as 1 log increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of participants who experienced viral breakthrough at Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144 have been presented.

    Time frame: At Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120,132, and 144

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs

    An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE occurred on or after the first dose date of study drug, SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events associated with liver injury and impaired liver function. The Safety analysis (SA) Population was defined as all participants who received at least one dose of study medication and have at least one post Baseline safety assessment.

    Time frame: Up to Week 144

  9. Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets

    Blood samples were collected to analyze the hematology parameters: WBC, basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144

  10. Change From Baseline in Hemoglobin (Hb)

    Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144

  11. Change From Baseline in Red Blood Cells (RBC)

    Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144

  12. Change From Baseline in Chemistry Parameters: ALT, Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)

    Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks 12,24,36,48,60,72,84,96,108,120,132,and 144

  13. Change From Baseline in Chemistry Parameters: Total Billirubin, Direct Bilirubin, Serum Creatinine

    Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144

  14. Change From Baseline in Chemistry Parameters: Albumin, Total Protein

    Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144

  15. Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridian, Phosphorus, Calcium and Fasting Blood Glucose.

    Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridian, phosphorus, calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144

  16. Change From Baseline in Chemistry Parameter: Creatinine Clearance Rate

    Blood samples were collected to analyze the chemistry parameter: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144

  17. Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR)

    Blood samples were collected to analyze the chemistry parameter: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144

07

Results

Posted Nov 4, 2019

Participant flow

This study was conducted to evaluate the efficacy and safety of Tenofovir Disoproxil Fumarate treatment in Chinese chronic hepatitis B (CHB) participants following failure of multiple Nucleos(t)ide analogues(NAs) at different centers in China.

Participant flow — Overall Study
MilestoneTenofovir Disoproxil Fumerate 300 mg
Started213
Completed204
Not completed9
Withdrew: Adverse event1
Withdrew: Protocol violation4
Withdrew: Pregnancy2
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144

HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Week 144. A 95 percent confidence interval (CI) was constructed by normal approximation and continuity correction method. Percentage of participants with serum HBV DNA \<20 IU/mL at Week 144 have been presented. The Modified Intent-to-treat (mITT) Population was defined as all recruited participants who received at least one dose of study medication.

Time frame:
At Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144
Percentage of ParticipantsTenofovir Disoproxil Fumerate 300 mg
Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 14477.0
SecondaryPercentage of Participants With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48 and 96

HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Weeks 48 and 96. Virological response was assessed by proportion of participants with serum serum HBV \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96. Percentage of participants with serum HBV DNA \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96 have been presented.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48 and 96
Percentage of ParticipantsTenofovir Disoproxil Fumerate 300 mg
Week 48, HBV DNA <20 IU/mL46.9
Week 48, HBV DNA <69 IU/mL76.5
Week 96, HBV DNA <20 IU/mL61.0
Week 96, HBV DNA <69 IU/mL84.0
SecondaryPercentage of Participants in the Subgroup With Confirmed Multi-drug Resistance Mutations at Baseline With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48, 96 and 144

Serum samples were collected and analyzed for HBV DNA levels at indicated time points. Resistance surveillance of the HBV polymerase gene were performed by direct sequencing for all participants at Baseline. Day 0 was considered as Baseline. Percentage of participants in the subgroup with confirmed multi-drug resistance mutations at Baseline with serum HBV DNA \<20 IU/mL and serum HBV DNA \<69 IU/mL at Weeks 48, 96 and 144 have been presented.

Time frame:
At Weeks 48, 96, and 144
Reported as:
Number · Percentage of Participants
Percentage of Participants in the Subgroup With Confirmed Multi-drug Resistance Mutations at Baseline With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48, 96 and 144
Percentage of ParticipantsTenofovir Disoproxil Fumerate 300 mg
Week 48, HBV DNA <20 IU/mL34.2
Week 48, HBV DNA <69 IU/mL60.5
Week 96, HBV DNA <20 IU/mL55.3
Week 96, HBV DNA <69 IU/mL76.3
Week 144, HBV DNA <20 IU/mL65.8
Week 144, HBV DNA <69 IU/mL84.2
SecondaryChange From Baseline in Logarithm to the Base 10 (Log 10) Reduction in Serum HBV DNA at Week 48, 96 and 144

Log10 reduction in serum HBV DNA was analyzed by patterns of mutation. The patterns of mutation were summarized by 2 categories. Category 1 included wild-type, LAM-R (Lamivudine-resistant), ADV-R (Adefovir-resistant) and ETV-R (Entecavir-resistant). Category 2 included Wild type, ADV-R single mutation, ADV-R double mutation and other mutation. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks 48,96, and 144
Reported as:
Mean · Log 10 (IU/mL)
Change From Baseline in Logarithm to the Base 10 (Log 10) Reduction in Serum HBV DNA at Week 48, 96 and 144
Log 10 (IU/mL)Tenofovir Disoproxil Fumerate 300 mg
Category 1, Week 48, Wild type, n=57-2.2 ± 1.63
Category 1,Week 96, Wild type, n=57-2.3 ± 1.61
Category 1,Week 144, Wild type, n=56-2.4 ± 1.54
Category 1,Week 48, ADV-R, n=38-3.0 ± 1.58
Category 1, Week 96, ADV-R, n=38-3.3 ± 1.53
Category 1, Week 144, ADV-R, n=38-3.5 ± 1.55
Category 1, Week 48, ETV-R, n=32-3.2 ± 1.49
Category 1, Week 96, ETV-R, n=32-3.4 ± 1.49
Category 1, Week 144, ETV-R, n=31-3.6 ± 1.47
Category 1, Week 48, LAM-R, n=93-3.1 ± 1.50
Category 1, Week 96, LAM-R, n=92-3.3 ± 1.59
Category 1, Week 144,LAM-R, n=91-3.2 ± 1.75
Category 2, Week 48, Wild type, n=57-2.2 ± 1.63
Category 2,Week 96, Wild type, n=57-2.3 ± 1.61
Category 2 Week 144, Wild type, n=56-2.4 ± 1.54
Category 2, Week 48, ADV-R single mutation, n=28-2.9 ± 1.69
Category 2, Week 96, ADV-R, single mutation, n=28-3.3 ± 1.65
Category 2, Week 144, ADV-R single mutation, n=28-3.5 ± 1.64
Category 2, Week 48,ADV-R double mutation, n=10-3.2 ± 1.26
Category 2, Week 96, ADV-R double mutation, n=10-3.3 ± 1.22
Category 1, Week 144, ADV-R double mutation, n=10-3.5 ± 1.36
Category 2, Week 48, other mutation, n=113-3.1 ± 1.48
Category 2, Week 96, other mutation, n=112-3.2 ± 1.53
Category 2, Week 144, other mutation, n=110-3.2 ± 1.67
SecondaryPercentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion or Hepatitis B s Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 48, 96, and 144

Serological response was assessed at Weeks 48, 96 and 144 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss, HBeAg Seroconversion, HBsAg Loss and HBsAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.

Time frame:
At Weeks 48, 96 and 144
Reported as:
Number · Percentage of Participants
Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion or Hepatitis B s Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 48, 96, and 144
Percentage of ParticipantsTenofovir Disoproxil Fumerate 300 mg
Week 48, HBeAg loss5.3
Week 48, HBeAg seroconversion2.6
Week 48, HBsAg loss0.5
Week 48, HBsAg seroconversion0
Week 96, HBeAg loss10.0
Week 96, HBeAg seroconversion2.6
Week 96, HBsAg loss0.5
Week 96, HBsAg seroconversion0.5
Week 144, HBeAg loss15.3
Week 144, HBeAg seroconversion4.7
Week 144, HBsAg loss1.1
Week 144, HBsAg seroconversion0.5
SecondaryPercentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 48, 96, and 144

Serological response was assessed at Weeks 48, 96 and 144 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.

Time frame:
At Weeks 48,96, and 144
Reported as:
Number · Percentage of Participants
Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 48, 96, and 144
Percentage of ParticipantsTenofovir Disoproxil Fumerate 300 mg
Week 48, HBsAg loss0
Week 48, HBsAg seroconversion0
Week 96, HBsAg loss0
Week 96, HBsAg seroconversion0
Week 144, HBsAg loss0
Week 144, HBsAg seroconversion0
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, and 144 in Participants Who Had Abnormal ALT at Baseline

Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization was defined as measurement less than or equal to the upper limit of the normal range. Normal range for ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, and 144 in Participants who had abnormal ALT at Baseline (Day 0) have been presented.

Time frame:
At Weeks 48, 96, and 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, and 144 in Participants Who Had Abnormal ALT at Baseline
Percentage of ParticipantsTenofovir Disoproxil Fumerate 300 mg
Week 4852.5
Week 9660.7
Week 14468.3
SecondaryPercentage of Participants Who Experienced Viral Breakthrough up to Week 144

Viral breakthrough was defined as 1 log increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of participants who experienced viral breakthrough at Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144 have been presented.

Time frame:
At Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120,132, and 144
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced Viral Breakthrough up to Week 144
Percentage of ParticipantsTenofovir Disoproxil Fumerate 300 mg
Week 240.5
Week 360
Week 480.5
Week 600
Week 720
Week 840
Week 960
Week 1080.5
Week 1200
Week 1320
Week 1440
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE occurred on or after the first dose date of study drug, SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events associated with liver injury and impaired liver function. The Safety analysis (SA) Population was defined as all participants who received at least one dose of study medication and have at least one post Baseline safety assessment.

Time frame:
Up to Week 144
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
ParticipantsTenofovir Disoproxil Fumerate 300 mg
Any TEAEs124
Serious TEAEs20
Non-serious TEAEs117
SecondaryChange From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets

Blood samples were collected to analyze the hematology parameters: WBC, basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144
Reported as:
Mean · Billion cells per liter
Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Billion cells per literTenofovir Disoproxil Fumerate 300 mg
Week 24, WBC, n=2080.19 ± 1.409
Week 48, WBC, n=2080.15 ± 1.470
Week 72, WBC, n=2070.13 ± 1.553
Week 96, WBC, n=2070.07 ± 1.504
Week 120, WBC, n=2040.10 ± 1.566
Week 144, WBC, n=2040.12 ± 1.484
Week 24, Neutrophils, n=2080.15 ± 1.322
Week 48, Neutrophils, n=2080.09 ± 1.419
Week 72, Neutrophils, n=2070.10 ± 1.388
Week 96, Neutrophils, n=2070.05 ± 1.414
Week 120, Neutrophils, n=2040.14 ± 1.400
Week 144, Neutrophils, n=2040.12 ± 1.293
Week 24, Lymphocytes, n=2080.02 ± 0.390
Week 48, Lymphocytes, n=2080.05 ± 0.396
Week 72, Lymphocytes, n=2070.02 ± 0.490
Week 96, Lymphocytes, n=2070.02 ± 0.439
Week 120, Lymphocytes, n=204-0.05 ± 0.459
Week 144, Lymphocyte, n=2040.00 ± 0.443
Week 24, Monocytes, n=208-0.001 ± 0.1069
Week 48, Monocytes, n=2080.004 ± 0.1163
Week 72, Monocytes, n=207-0.010 ± 0.1177
Week 96, Monocytes, n=207-0.009 ± 0.1123
Week 120, Monocytes, n=204-0.006 ± 0.1209
Week 144, Monocytes, n=204-0.008 ± 0.1285
Week 24, Eosinophils, n=2080.02 ± 0.153
Week 48, Eosinophils, n=208-0.00 ± 0.079
Week 72, Eosinophils, n=2070.02 ± 0.225
Week 96, Eosinophils, n=207-0.00 ± 0.076
Week 120, Eosinophils, n=2040.00 ± 0.092
Week 144, Eosinophils, n=2040.00 ± 0.097
Week 24, Basophils, n=2080.00 ± 0.027
Week 48, Basophils, n=2080.00 ± 0.023
Week 72, Basophils, n=207-0.00 ± 0.025
Week 96, Basophils, n=207-0.00 ± 0.024
Week 120, Basophils, n=2030.00 ± 0.025
Week 144, Basophils, n=2030.00 ± 0.025
Week 24, Platelets, n=2083.5 ± 27.07
Week 48, Platelets, n=2082.5 ± 29.38
Week 72, Platelets, n=2071.9 ± 33.74
Week 96, Platelets, n=2073.9 ± 33.20
Week 120, Platelets, n=2047.2 ± 33.48
Week 144, Platelets, n=2049.3 ± 34.74
SecondaryChange From Baseline in Hemoglobin (Hb)

Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144
Reported as:
Mean · Grams per liter
Change From Baseline in Hemoglobin (Hb)
Grams per literTenofovir Disoproxil Fumerate 300 mg
Week 24, n=2082.4 ± 6.53
Week 48, n=208-0.2 ± 7.04
Week 72, n=207-0.2 ± 7.68
Week 96, n=207-1.0 ± 8.67
Week 120, n=204-1.0 ± 8.86
Week 144, n=204-0.2 ± 9.24
SecondaryChange From Baseline in Red Blood Cells (RBC)

Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144
Reported as:
Mean · Trillion cells per liter
Change From Baseline in Red Blood Cells (RBC)
Trillion cells per literTenofovir Disoproxil Fumerate 300 mg
Week 24, n=2080.13 ± 0.254
Week 48, n=2080.05 ± 0.259
Week 72, n=2070.07 ± 0.268
Week 96, n=2070.02 ± 0.294
Week 120, n=2040.08 ± 0.291
Week 144, n=2040.06 ± 0.305
SecondaryChange From Baseline in Chemistry Parameters: ALT, Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)

Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks 12,24,36,48,60,72,84,96,108,120,132,and 144
Reported as:
Mean · International units per liter
Change From Baseline in Chemistry Parameters: ALT, Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)
International units per literTenofovir Disoproxil Fumerate 300 mg
Week 12, ALT, n=2091.66 ± 54.582
Week 24, ALT, n=208-2.80 ± 51.195
Week 36, ALT, n=209-4.57 ± 51.811
Week 48, ALT, n=208-7.07 ± 50.986
Week 60, ALT, n=208-9.20 ± 50.312
Week 72, ALT, n=207-8.12 ± 51.538
Week 84, ALT, n=207-10.53 ± 51.781
Week 96, ALT, n=207-9.13 ± 54.323
Week 108, ALT, n=205-11.25 ± 52.277
Week 120, ALT, n=205-11.95 ± 51.584
Week 132, ALT, n=205-11.56 ± 51.594
Week 144, ALT, n=204-10.97 ± 53.326
Week 12, AST, n=209-1.68 ± 44.258
Week 24, AST, n=208-3.20 ± 44.506
Week 36, AST, n=209-2.93 ± 45.755
Week 48, AST, n=205-4.23 ± 45.393
Week 60, AST, n=208-4.68 ± 44.969
Week 72, AST, n=207-4.43 ± 44.901
Week 84, AST, n=207-5.56 ± 45.435
Week 96, AST, n=207-4.37 ± 46.008
Week 108, AST, n=205-5.81 ± 45.818
Week 120, AST, n=205-5.67 ± 45.645
Week 132, AST, n=205-6.05 ± 45.290
Week 144, AST, n=204-5.85 ± 46.176
Week 12, ALP, n=2084.46 ± 11.718
Week 24, ALP, n=2087.22 ± 13.819
Week 36, ALP, n=2096.27 ± 12.609
Week 48, ALP, n=2088.24 ± 12.225
Week 60, ALP, n=2088.75 ± 14.321
Week 72, ALP, n=20710.06 ± 16.259
Week 84, ALP, n=2077.32 ± 14.478
Week 96, ALP, n=2078.73 ± 13.854
Week 108, ALP, n=2057.62 ± 15.102
Week 120, ALP, n=2057.54 ± 17.844
Week 132, ALP, n=2057.36 ± 15.802
Week 144, ALP, n=2057.14 ± 15.099
Week 12, GGT, n=208-1.83 ± 18.966
Week 24, GGT, n=208-1.83 ± 19.853
Week 36, GGT, n=209-2.25 ± 20.205
Week 48, GGT, n=207-1.90 ± 20.760
Week 60, GGT, n=208-1.25 ± 22.512
Week 72, GGT, n=207-1.45 ± 23.700
Week 84, GGT, n=207-2.10 ± 21.532
Week 96, GGT, n=207-2.50 ± 21.436
Week 108, GGT, n=205-1.62 ± 22.053
Week 120, GGT, n=205-1.61 ± 22.872
Week 132, GGT, n=205-1.80 ± 21.897
Week 144, GGT, n=203-0.76 ± 25.363
Week 12, CK, n=20610.84 ± 525.680
Week 24, CK, n=198-9.28 ± 108.221
Week 36, CK, n=20113.87 ± 315.156
Week 48 CK, n=206-21.58 ± 202.083
Week 60, CK, n=205-22.26 ± 207.666
Week 72, CK, n=206-13.45 ± 209.963
Week 84, CK, n=207-17.40 ± 204.800
Week 96, CK, n=20726.58 ± 415.775
Week 108, CK, n=199-20.58 ± 211.398
Week 120, CK, n=2030.59 ± 261.655
Week 132, CK, n=204-19.34 ± 214.775
Week 144, CK, n=204-7.17 ± 270.074
Week 12, LDH, n=2091.66 ± 54.582
Week 24, LDH, n=208-2.80 ± 51.195
Week 36, LDH, n=209-4.57 ± 51.811
Week 48, LDH, n=208-7.07 ± 50.986
Week 60, LDH, n=208-9.20 ± 50.312
Week 72, LDH, n=207-8.12 ± 51.538
Week 84, LDH, n=207-10.53 ± 51.781
Week 96, LDH, n=207-9.13 ± 54.323
Week 108, LDH, n=205-11.25 ± 52.277
Week 120, LDH, n=205-11.95 ± 51.584
Week 132, LDH, n=205-11.56 ± 51.594
Week 144, LDH, n=204-10.97 ± 53.326
SecondaryChange From Baseline in Chemistry Parameters: Total Billirubin, Direct Bilirubin, Serum Creatinine

Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Reported as:
Mean · Micromoles per liter
Change From Baseline in Chemistry Parameters: Total Billirubin, Direct Bilirubin, Serum Creatinine
Micromoles per literTenofovir Disoproxil Fumerate 300 mg
Week 12, total bilirubin, n=209-0.506 ± 4.8201
Week 24, total bilirubin, n=208-0.755 ± 5.0494
Week 36, total bilirubin, n=209-0.878 ± 5.0063
Week 48, total bilirubin, n=207-0.167 ± 4.8371
Week 60, total bilirubin, n=208-0.334 ± 4.9175
Week 72, total bilirubin, n=207-1.209 ± 5.1706
Week 84, total bilirubin, n=207-1.112 ± 5.0813
Week 96, total bilirubin, n=207-0.780 ± 5.1218
Week 108, total bilirubin, n=205-0.795 ± 5.7857
Week 120, total bilirubin, n=205-1.021 ± 5.3998
Week 132, total bilirubin, n=205-1.471 ± 4.8998
Week 144, total bilirubin, n=204-0.869 ± 5.4163
Week 12, direct bilirubin, n=209-0.181 ± 2.6421
Week 24, direct bilirubin, n=208-0.360 ± 2.2236
Week 36, direct bilirubin, n=208-0.541 ± 3.2564
Week 48, direct bilirubin, n=207-0.085 ± 3.0478
Week 60, direct bilirubin, n=208-0.111 ± 3.1364
Week 72, direct bilirubin, n=207-0.654 ± 3.7846
Week 84, direct bilirubin, n=207-0.797 ± 3.6592
Week 96, direct bilirubin, n=207-0.711 ± 3.3849
Week 108, direct bilirubin, n=205-0.632 ± 3.4657
Week 120, direct bilirubin, n=205-0.802 ± 3.6175
Week 132, direct bilirubin, n=205-0.805 ± 3.1588
Week 144, direct bilirubin, n=204-0.573 ± 2.8964
Week 12, serum creatinine, n=2092.94 ± 7.089
Week 24, serum creatinine, n=2081.16 ± 6.934
Week 36, serum creatinine, n=2090.67 ± 7.743
Week 48, serum creatinine, n=2081.43 ± 7.480
Week 60, serum creatinine, n=2080.25 ± 8.181
Week 72, serum creatinine, n=206-1.00 ± 7.583
Week 84, serum creatinine, n=207-0.65 ± 9.075
Week 96, serum creatinine, n=2070.22 ± 9.013
Week 108, serum creatinine, n=204-0.28 ± 8.511
Week 120, serum creatinine, n=205-1.22 ± 8.844
Week 132, serum creatinine, n=205-0.81 ± 8.250
Week 144, serum creatinine, n=203-1.28 ± 8.610
SecondaryChange From Baseline in Chemistry Parameters: Albumin, Total Protein

Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Reported as:
Mean · Grams per liter
Change From Baseline in Chemistry Parameters: Albumin, Total Protein
Grams per literTenofovir Disoproxil Fumerate 300 mg
Week 12, albumin, n=2090.22 ± 2.766
Week 24, albumin, n=2080.54 ± 2.722
Week 36, albumin, n=2090.04 ± 2.545
Week 48, albumin, n=2080.24 ± 2.687
Week 60, albumin, n=2080.38 ± 2.757
Week 72, albumin, n=2070.49 ± 2.890
Week 84, albumin, n=207-0.03 ± 3.021
Week 96, albumin, n=2070.13 ± 2.980
Week 108, albumin, n=205-0.56 ± 2.932
Week 120, albumin, n=2050.17 ± 3.272
Week 132, albumin, n=2050.51 ± 2.942
Week 144, albumin, n=2040.48 ± 3.171
Week 12, total protein, n=2090.31 ± 4.220
Week 24, total protein, n=2070.92 ± 4.322
Week 36, total protein, n=209-0.30 ± 4.280
Week 48, total protein, n=208-0.53 ± 4.240
Week 60, total protein, n=208-0.32 ± 4.387
Week 72, total protein, n=207-0.26 ± 4.540
Week 84, total protein, n=207-0.57 ± 5.158
Week 96, total protein, n=207-0.44 ± 5.240
Week 108, total protein, n=205-0.21 ± 4.855
Week 120, total protein, n=2050.95 ± 5.361
Week 132, total protein, n=2051.00 ± 4.494
Week 144, total protein, n=2040.94 ± 4.794
SecondaryChange From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridian, Phosphorus, Calcium and Fasting Blood Glucose.

Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridian, phosphorus, calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Reported as:
Mean · Millimoles per liter
Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridian, Phosphorus, Calcium and Fasting Blood Glucose.
Millimoles per literTenofovir Disoproxil Fumerate 300 mg
Week 12, BUN, n=209-0.020 ± 1.0496
Week 24, BUN, n=2080.069 ± 1.0725
Week 36, BUN, n=2090.081 ± 1.0921
Week 48, BUN, n=2080.075 ± 1.0907
Week 60, BUN, n=2080.078 ± 1.0372
Week 72, BUN, n=2060.119 ± 1.1114
Week 84, BUN, n=2070.164 ± 1.0819
Week 96, BUN, n=2070.100 ± 1.0482
Week 108, BUN, n=2040.051 ± 1.1279
Week 120, BUN, n=2050.110 ± 1.1672
Week 132, BUN, n=2050.090 ± 1.1443
Week 144, BUN, n=2030.193 ± 1.2236
Week 12, Potassium, n=209-0.029 ± 0.3391
Week 24, Potassium, n=2080.028 ± 0.3659
Week 36, Potassium, n=2090.073 ± 0.3681
Week 48, Potassium, n=2080.016 ± 0.3206
Week 60, Potassium, n=2080.014 ± 0.3622
Week 72, Potassium, n=206-0.032 ± 0.3402
Week 84, Potassium, n=2060.022 ± 0.3617
Week 96, Potassium, n=206-0.019 ± 0.3357
Week 108, Potassium, n=204-0.023 ± 0.3326
Week 120, Potassium, n=204-0.002 ± 0.3221
Week 132, Potassium, n=2040.001 ± 0.3531
Week 144, Potassium, n=204-0.000 ± 0.3851
Week 12, Sodium, n=2090.31 ± 2.227
Week 24, Sodium, n=2080.52 ± 2.514
Week 36, Sodium, n=2090.23 ± 2.437
Week 48, Sodium, n=2080.40 ± 2.781
Week 60, Sodium, n=2080.59 ± 2.569
Week 72, Sodium, n=2060.47 ± 2.631
Week 84, Sodium, n=2070.54 ± 2.689
Week 96, Sodium, n=2060.44 ± 2.388
Week 108, Sodium, n=2040.05 ± 2.352
Week 120, Sodium, n=2040.03 ± 3.332
Week 132, Sodium, n=2040.35 ± 2.672
Week 144, Sodium, n=2040.13 ± 2.642
Week 12, Chloridion n=209-0.23 ± 3.271
Week 24, Chloridion, n=208-0.32 ± 3.834
Week 36, Chloridion, n=209-0.50 ± 3.453
Week 48, Chloridion, n=208-0.31 ± 3.601
Week 60, Chloridion, n=208-0.37 ± 3.305
Week 72, Chloridion, n=206-0.30 ± 3.388
Week 84, Chloridion, n=207-0.38 ± 3.519
Week 96, Chloridion, n=2060.04 ± 3.418
Week 108, Chloridion, n=204-0.27 ± 3.587
Week 120, Chloridion, n=204-0.17 ± 4.309
Week 132, Chloridion, n=204-0.14 ± 3.717
Week 144, Chloridion, n=204-0.28 ± 3.855
Week 12, Phosphorus, n=209-0.018 ± 0.1607
Week 24, Phosphorus, n=208-0.001 ± 0.1662
Week 36, Phosphorus, n=209-0.001 ± 0.1779
Week 48, Phosphorus, n=208-0.008 ± 0.1634
Week 60, Phosphorus, n=2080.004 ± 0.1685
Week 72, Phosphorus, n=207-0.011 ± 0.1713
Week 84, Phosphorus, n=207-0.023 ± 0.1736
Week 96, Phosphorus, n=206-0.019 ± 0.1669
Week 108, Phosphorus, n=201-0.008 ± 0.1779
Week 120, Phosphorus, n=203-0.015 ± 0.1687
Week 132, Phosphorus, n=2040.002 ± 0.1757
Week 144, Phosphorus, n=204-0.016 ± 0.1692
Week 12, Calcium, n=209-0.005 ± 0.1172
Week 24, Calcium, n=208-0.027 ± 0.1289
Week 36, Calcium, n=209-0.030 ± 0.1432
Week 48, Calcium, n=208-0.041 ± 0.1375
Week 60, Calcium, n=208-0.038 ± 0.1365
Week 72, Calcium, n=207-0.061 ± 0.1296
Week 84, Calcium, n=207-0.060 ± 0.1321
Week 96, Calcium, n=206-0.051 ± 0.1198
Week 108, Calcium, n=204-0.062 ± 0.1290
Week 120, Calcium, n=204-0.051 ± 0.1370
Week 132, Calcium, n=204-0.052 ± 0.1235
Week 144, Calcium, n=204-0.050 ± 0.1393
Week 12, Fasting blood glucose, n=205-0.088 ± 1.0006
Week 24, fasting blood glucose, n=208-0.087 ± 0.8926
Week 36, fasting blood glucose, n=208-0.150 ± 0.9535
Week 48, fasting blood glucose, n=208-0.234 ± 0.8378
Week 60, fasting blood glucose, n=208-0.206 ± 0.8658
Week 72, fasting blood glucose, n=202-0.187 ± 0.8626
Week 84, fasting blood glucose, n=207-0.143 ± 1.0564
Week 96, fasting blood glucose, n=206-0.132 ± 1.1423
Week 108, fasting blood glucose, n=200-0.230 ± 0.9042
Week 120, fasting blood glucose, n=204-0.180 ± 0.9873
Week 132, fasting blood glucose, n=204-0.151 ± 0.9312
Week 144, fasting blood glucose, n=204-0.070 ± 1.0163
SecondaryChange From Baseline in Chemistry Parameter: Creatinine Clearance Rate

Blood samples were collected to analyze the chemistry parameter: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Reported as:
Mean · Milliliter per minute
Change From Baseline in Chemistry Parameter: Creatinine Clearance Rate
Milliliter per minuteTenofovir Disoproxil Fumerate 300 mg
Week 12, n=208-4.564 ± 11.1192
Week 24, n=208-2.213 ± 11.2288
Week 36, n=209-2.311 ± 12.4693
Week 48, n=208-3.667 ± 12.3427
Week 60, n=208-2.053 ± 13.9768
Week 72, n=206-0.519 ± 13.1580
Week 84, n=207-1.065 ± 15.0315
Week 96, n=207-2.378 ± 13.8827
Week 108, n=204-2.512 ± 13.4608
Week 120, n=203-0.742 ± 14.3800
Week 132, n=205-1.499 ± 13.3816
Week 144, n=203-0.821 ± 13.8173
SecondaryChange From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR)

Blood samples were collected to analyze the chemistry parameter: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Reported as:
Mean · Grams per liter
Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR)
Grams per literTenofovir Disoproxil Fumerate 300 mg
Week 12, n=209-2.93 ± 7.250
Week 24, n=209-1.11 ± 6.798
Week 36, n=209-0.63 ± 7.558
Week 48, n=208-1.31 ± 7.378
Week 60, n=208-0.12 ± 8.004
Week 72, n=2080.84 ± 7.619
Week 84, n=2070.42 ± 8.731
Week 96, n=207-0.17 ± 8.752
Week 108, n=2050.42 ± 8.379
Week 120, n=2050.77 ± 8.826
Week 132, n=2050.60 ± 8.098
Week 144, n=2040.95 ± 8.313

Adverse events

Collected over On-treatment non-serious adverse events and serious adverse events were collected up to 144 weeks from the start of the treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir Disoproxil Fumerate 300 mg1/213 (0.5%)20/213 (9.4%)117/213 (54.9%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTenofovir Disoproxil Fumerate 300 mg
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/213
CholelithiasisHepatobiliary disorders2/213
Fibula fractureInjury, poisoning and procedural complications2/213
Tibia fractureInjury, poisoning and procedural complications2/213
Cholecystitis acuteHepatobiliary disorders2/213
Testicular seminoma (pure)Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/213
Bile duct stoneHepatobiliary disorders1/213
Cholecystitis chronicHepatobiliary disorders1/213
Cervical vertebral fractureInjury, poisoning and procedural complications1/213
Limb injuryInjury, poisoning and procedural complications1/213
Most frequent other events
Showing 10 of 115
Most frequent other events
EventTenofovir Disoproxil Fumerate 300 mg
Upper respiratory tract infectionInfections and infestations28/213
Blood creatine phosphokinase increasedInvestigations12/213
HypophosphataemiaMetabolism and nutrition disorders8/213
Hepatic steatosisHepatobiliary disorders7/213
Urinary tract infectionInfections and infestations4/213
DiarrhoeaGastrointestinal disorders4/213
NephrolithiasisRenal and urinary disorders4/213
InsomniaPsychiatric disorders4/213
HypertensionVascular disorders4/213
Blood uric acid increasedInvestigations3/213

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tenofovir Disoproxil Fumerate 300 mg
Mean42.3 ± 10.29
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir Disoproxil Fumerate 300 mg
Female27
Male186
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tenofovir Disoproxil Fumerate 300 mg
Asian213
08

Study locations

12 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510060, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510150, China
  • GSK Investigational Site
    Changchun, Jilin, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310000, China
  • GSK Investigational Site
    Beijing, 100034, China
  • GSK Investigational Site
    Beijing, 100044, China
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Beijing, 100054, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Zhengzhou, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Aug 2018, 40 months.

Results were first posted in Nov 2019, 1 year 2 months after primary completion.

Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2014
First posted
Jul 21, 2014
StartActual
Mar 18, 2015
Primary completionActual
Aug 14, 2018
CompletionActual
Aug 14, 2018
Results first posted
Nov 4, 2019
Last update
Nov 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02195518
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Mar 18, 2015
Primary completion
Aug 14, 2018
Completion
Aug 14, 2018
Results posted
Nov 4, 2019
Last update
Nov 4, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion